Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds

The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.

Related Keywords

Paris ,France General ,France ,United Kingdom ,Genentech Rozlytrek ,Denis Horgan ,Arnaud Bayle ,Bayer Vitrakvi ,Global Policy Committee ,European Society For Medical Oncology Congress ,Europeans Medicines Agency ,Gustave Roussy Cancer Center ,European Alliance For Personalized Medicine ,European Society ,Medical Oncology Congress ,Policy Committee ,Precision Oncology News ,Clinical Actionability ,Genomic Medicine Plan ,European Alliance ,Personalized Medicine ,